SMS Pharmaceuticals reported a consolidated profit after tax (PAT) of ₹20.91 crore for the first quarter ended June 30, 2026 (Q1FY27), marking an 8% year-on-year increase. The company’s revenue from operations rose 6% to ₹206.96 crore, supported by diversified growth in high-value active pharmaceutical ingredients (APIs). This performance underscores the effectiveness of its backward integration strategy and shift toward high-value therapeutic areas, which have improved unit economics despite stable EBITDA margins.

The financial results were approved by the Board of Directors in its meeting held on July 31, 2026, and reviewed by the Audit Committee. The Statutory Auditors carried out a limited review of the standalone and consolidated financial statements. The filing was submitted pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.

Financial Performance

Consolidated revenue from operations stood at ₹206.96 crore in Q1FY27, compared to ₹196.05 crore in the corresponding period of the previous year. Cost of goods sold (COGS) increased marginally by 2% to ₹132.03 crore, enabling gross profit to jump 12% to ₹74.93 crore. Consequently, gross margins expanded by 217 basis points to 36%, up from 34% in Q1FY26.

EBITDA grew 4% to ₹40.95 crore, maintaining a margin of 20%. Profit before tax (PBT) rose 12% to ₹27.20 crore, aided by a 195% surge in other income to ₹1.74 crore. After accounting for finance costs of ₹5.50 crore and taxes of ₹7.00 crore, net profit before share of associates was ₹20.20 crore. Including the share of associate profit, total consolidated PAT reached ₹20.91 crore.

Strategic Developments

SMS Pharmaceuticals is executing a ₹280 crore capital expenditure programme expected to be completed by FY27. This investment focuses on capacity expansion for existing APIs and building capabilities for new pipeline products. Additionally, the Board approved an infusion of up to ₹50 crore as a loan into its subsidiary, SMS Peptides Private Limited, to support its dedicated peptide R&D facility. This follows an earlier ₹8 crore investment made in FY26.

Geographically, North America accounted for 32% of sales. Therapeutically, Anti-Retro Viral (ARV) and Anti-inflammatory products emerged as the largest contributors, each accounting for 32% of the portfolio. The company also announced the completion of four DMF/CEP filings, putting it on track to meet its FY27 target of 10 filings.

What the Numbers Show

The divergence between stable EBITDA margins and expanding gross margins suggests operational leverage is being captured through product mix optimization rather than pure volume growth. With high-value products now constituting 51% of the portfolio (up from 30% in FY21), SMS Pharmaceuticals is successfully mitigating price erosion risks common in the generics landscape. However, the significant increase in other income warrants monitoring, as it contributed disproportionately to PBT growth compared to operational earnings.

SMS Pharmaceuticals Limited has rescheduled its Board of Directors meeting from August 1, 2026, to July 31, 2026, to consider and approve the unaudited financial results for the first quarter ended June 30, 2026 (Q1FY26). The change in date was necessitated by unavoidable administrative exigencies, ensuring the timely disclosure of quarterly performance metrics to stakeholders.

The company informed the Bombay Stock Exchange and the National Stock Exchange of India Ltd. on July 29, 2026, regarding the preponement. The Board will transact the same business as previously intimated, primarily focusing on the approval of standalone and consolidated financial statements for Q1FY26. This procedural adjustment ensures compliance with regulatory timelines for result announcements.

Trading Window Status

In accordance with the Company's Code of Conduct for Prevention of Insider Trading and the amended SEBI (Prohibition of Insider Trading) Regulations, 2015, the trading window for designated persons remains closed. The closure began on July 1, 2026, and will remain in effect until August 2, 2026, inclusive. The trading window is scheduled to reopen on August 3, 2026.

Key Details

The notification was issued pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. Thirumalesh Tumma, Company Secretary & Compliance Officer, signed the communication, confirming the adherence to insider trading regulations during the sensitive period leading up to the result announcement.